StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Wednesday. The firm set a “hold” rating on the stock.

Several other equities research analysts also recently issued reports on EKSO. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Ekso Bionics in a research report on Tuesday, March 4th. Lake Street Capital dropped their price target on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th.

Ekso Bionics Stock Performance

Shares of NASDAQ EKSO opened at $0.43 on Wednesday. Ekso Bionics has a 12 month low of $0.34 and a 12 month high of $1.53. The stock has a 50 day moving average of $0.56 and a 200-day moving average of $0.78. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $10.68 million, a P/E ratio of -0.66 and a beta of 1.43.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). The company had revenue of $5.09 million during the quarter, compared to analyst estimates of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. As a group, equities research analysts predict that Ekso Bionics will post -0.48 EPS for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.